Meeting
2017 ASCO Annual Meeting
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
Authors
Jiaying Chen
Fudan University Shanghai Cancer Center, Shanghai, China
Jiaying Chen , Qinghai Ji , Junning Cao , Dongmei Ji , Chunmei Bai , Yansong Lin , Bin Pan , Guofang Sun , Jing Li , Chuan Qi , Ye Hua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02614495
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6037)
DOI
10.1200/JCO.2017.35.15_suppl.6037
Abstract #
6037
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
First Author: Jaume Capdevila
Poster
2012 ASCO Annual Meeting
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
First Author: Martin Schlumberger
Poster
2021 ASCO Annual Meeting
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.
First Author: Daniel Pink
Poster
2016 ASCO Annual Meeting
Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.
First Author: Yongkun Sun